In a move that will grow its oncology pipeline, Gilead Sciences is spending more than $3 billion to buy the German biotech Tubulis, the companies said Tuesday. The deal includes an upfront payment of $3.15 billion and up to $1.85 billion more if certain milestones are reached.
It also highlights both the therapeutic and commercial promise of antibody-drug conjugates , the next-generation chemotherapy treatments that the privately held Tubulis is developing. Gilead’s latest move comes just months after it said it would acquire Arcellx in a deal worth $7.8 billion.
The two companies had already been working together on a multiple myeloma CAR-T therapy that could be approved later this year. Gilead last month also announced that it was buying Ouro Therapeutics, which is focused on drugs for autoimmune disease, for up to $2.18 billion.
Continue to STAT+ to read the full story...
STAT News published a clinical update in Research Highlights on 07 Apr 2026.
The item focuses on STAT+: Gilead to buy cancer biotech Tubulis for more than $3 billion.
Review the original article for the full source wording and details.